Please login to the form below

Not currently logged in
Email:
Password:

Sorbent appoints new chair and chief medical officer

Randall Woods and Howard Dittrich join US biotech

US biotech Sorbent has hired Howard Dittrich as its first chief medical officer and appointed Randall Woods as chair of the board of directors.

Both men have previously worked together at NovaCardia, a company Dittrichco-founded and which was later taken over by Merck & Co.

Dittrich was chief medical officer and senior VP of clinical and regulatory affairs at NovoCardia, while Woods was its president and CEO.

Woods subsequently also held these roles at Sequel Pharmaceuticals, a spinout from the acquisition of NovaCardia by Merck.

"Howard and Randy are joining the Sorbent leadership team at an exciting time,” said Dr Detlef Albrecht, president and CEO of California-based Sorbent.

“With data in hand from our phase IIa study of CLP1001, we are setting forth clinical plans to advance the development of this compound in heart failure. Howard and Randy each bring a wealth of highly relevant experience in developing successful cardiovascular agents, and we look forward to benefitting from their contributions and their insights."

Dittrich has also held multiple senior positions with Molecular Biosystems and Alliance Pharmaceuticals, where he obtained US Food and Drug Administration approval for two cardiovascular imaging agents and completed phase III clinical trials on a third compound.

Previous positions for Woods include president and CEO of the biotech Corvas International, president of Boehringer Mannheim's US pharma operations, and various sales and marketing positions at Eli Lilly & Company where he spent more than 20 years.

24th April 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Sciterion

Sciterion is an award winning specialist healthcare communications consultancy within the Havas Health network of companies. We exist to make...

Latest intelligence

NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...
Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....

Infographics